JPWO2021201171A1 - - Google Patents
Info
- Publication number
- JPWO2021201171A1 JPWO2021201171A1 JP2022512664A JP2022512664A JPWO2021201171A1 JP WO2021201171 A1 JPWO2021201171 A1 JP WO2021201171A1 JP 2022512664 A JP2022512664 A JP 2022512664A JP 2022512664 A JP2022512664 A JP 2022512664A JP WO2021201171 A1 JPWO2021201171 A1 JP WO2021201171A1
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020066150 | 2020-04-01 | ||
| JP2020066150 | 2020-04-01 | ||
| PCT/JP2021/014030 WO2021201171A1 (ja) | 2020-04-01 | 2021-03-31 | 神経炎症の抑制、そのための組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2021201171A1 true JPWO2021201171A1 (https=) | 2021-10-07 |
| JPWO2021201171A5 JPWO2021201171A5 (https=) | 2022-12-20 |
| JP7699831B2 JP7699831B2 (ja) | 2025-06-30 |
Family
ID=77929171
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022512664A Active JP7699831B2 (ja) | 2020-04-01 | 2021-03-31 | 神経炎症の抑制、そのための組成物及び方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US12605368B2 (https=) |
| EP (1) | EP4129340B1 (https=) |
| JP (1) | JP7699831B2 (https=) |
| CN (1) | CN115361973A (https=) |
| WO (1) | WO2021201171A1 (https=) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015083750A1 (ja) * | 2013-12-05 | 2015-06-11 | 国立大学法人京都大学 | 神経新生に関する化合物及び医薬組成物 |
| WO2018043674A1 (ja) * | 2016-08-31 | 2018-03-08 | 国立大学法人京都大学 | 神経新生を活性化するための組成物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9745323B2 (en) | 2012-07-30 | 2017-08-29 | Kyoto University | Compound and pharmaceutical composition for neuropsychological disorder or malignant tumor |
| CA2912345C (en) | 2013-05-16 | 2020-10-06 | Sumitomo Dainippon Pharma Co., Ltd. | Transplantation adjuvant in cell therapy using neural progenitor cells |
| WO2015107945A1 (ja) | 2014-01-17 | 2015-07-23 | ソニー株式会社 | スイッチ素子および記憶装置 |
| CN106535890A (zh) | 2014-03-20 | 2017-03-22 | 萨穆梅德有限公司 | 5‑取代的吲唑‑3‑羧酰胺及其制备和应用 |
| WO2018029793A1 (ja) | 2016-08-09 | 2018-02-15 | 株式会社Ａｏｂ慧央グループ | Ｉｌ－６産生抑制剤、抗炎症剤、抗神経変性疾患剤、抗精神神経疾患剤、医薬品及び食品 |
| US10604514B2 (en) | 2017-10-19 | 2020-03-31 | Samumed, Llc | 6-(5-membered heteroaryl)isoquinolin-3-yl carboxamides and preparation and use thereof |
-
2021
- 2021-03-31 JP JP2022512664A patent/JP7699831B2/ja active Active
- 2021-03-31 CN CN202180026757.6A patent/CN115361973A/zh active Pending
- 2021-03-31 US US17/915,751 patent/US12605368B2/en active Active
- 2021-03-31 EP EP21779632.5A patent/EP4129340B1/en active Active
- 2021-03-31 WO PCT/JP2021/014030 patent/WO2021201171A1/ja not_active Ceased
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015083750A1 (ja) * | 2013-12-05 | 2015-06-11 | 国立大学法人京都大学 | 神経新生に関する化合物及び医薬組成物 |
| WO2018043674A1 (ja) * | 2016-08-31 | 2018-03-08 | 国立大学法人京都大学 | 神経新生を活性化するための組成物 |
Non-Patent Citations (5)
| Title |
|---|
| ACTA NEUROPATHOLOGICA COMMUNICATIONS, vol. 7, no. 46, JPN6025010004, 2019, pages 1 - 15, ISSN: 0005550152 * |
| MELCHIOR,BENOIT ET AL.: "ANTI-INFLAMMATORY EFFECTS OF SM07883, A NOVEL, POTENT, AND SELECTIVE ORAL DYRK1A INHIBITOR IN NEUROD", ALZHEIMAER'S AND DEMENTIA, vol. 15, no. 7, JPN6021014794, 2019, pages 216, XP085869764, ISSN: 0005550149, DOI: 10.1016/j.jalz.2019.06.4563 * |
| WOO,HANWOONG ET AL.: "The novel DYRK1A inhibitor KD03 alters neuroinflammation in BV2 microglial cells,wild-type, and Alzh", IBRO REPORTS, vol. 6, JPN6021014792, 2019, pages 130, ISSN: 0005550148 * |
| 日本臨床, vol. 61, no. 3, JPN6021044163, 2003, pages 463 - 468, ISSN: 0005550151 * |
| 日本臨床, vol. Vol.72, Suppl.5, JPN6021044166, 2014, pages 453 - 458, ISSN: 0005550150 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20230117374A1 (en) | 2023-04-20 |
| EP4129340A1 (en) | 2023-02-08 |
| EP4129340A4 (en) | 2024-08-07 |
| US12605368B2 (en) | 2026-04-21 |
| EP4129340B1 (en) | 2025-12-03 |
| CN115361973A (zh) | 2022-11-18 |
| WO2021201171A1 (ja) | 2021-10-07 |
| JP7699831B2 (ja) | 2025-06-30 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220930 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240325 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250313 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250423 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20250605 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20250611 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7699831 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |